Morgan Stanley lowered the firm’s price target on Veracyte (VCYT) to $37 from $48 and keeps an Underweight rating on the shares. The firm updated its model following Q4 results.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte Inc. Signals Durable Growth in Earnings Call
- Veracyte: Accelerating Growth, Expanding Margins, and Pipeline-Driven Upside Support a Raised $48 Price Target
- Veracyte reports Q4 EPS 51c, consensus 41c
- Veracyte sees FY26 revenue $570M-$582M, consensus $570.3M
- VCYT Earnings this Week: How Will it Perform?